Biohaven to present anti-seizure results of BHV-7000

Biohaven will present an oral and poster presentation demonstrating the preclinical efficacy and initial Phase 1 safety and tolerability of BHV-7000, a novel activator of heteromeric Kv7.2/7.3 potassium channels, on the 2023 American Society for Experimental Neurotherapeutics Annual Meeting virtual platform, taking place March 13-15, 2023. Steven Dworetzky, SVP of Kv7 Strategy and Development at Biohaven, said, "The preclinical data we are presenting at ASENT today demonstrate that activating Kv7.2/7.3 with BHV-7000, a compound that is structurally and pharmacologically distinct from ezogabine, produced concentration-dependent hyperpolarization of the resting membrane potential, potentiated meaningful increases in action potential threshold, exhibited significantly lower GABAA activity than ezogabine, and delivered potent anti-seizure efficacy in the maximal electroshock seizure model, without negatively impacting neurobehavior. Further, in the Phase 1 single ascending dose / multiple ascending dose clinical trial, BHV-7000 was well-tolerated at single doses up to 100 mg and multiple doses up to 40 mg per day for 15 days. Most adverse events were mild and resolved spontaneously, and there were no serious or severe adverse events or dose-limiting toxicities reported. Importantly, in BHV-7000 treated subjects in the MAD study, CNS-related adverse events typically associated with other anti-seizure medications were not reported."